Author

T. Jamaspishvilli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Assay:imaging· 1

Frequent Co-Authors

C. Jackson· 2 shared D. M. Berman· 2 shared D. R. Siemens· 2 shared M. Koti· 2 shared S. Chenard· 2 shared A. Garven· 1 shared B. Ravenscroft· 1 shared C. Hardy· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Jackson

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Increased stromal densities of B cells, CD103+ cells, and CD163+ M2-like macrophages associate with poor clinical outcomes in BCG treated non-muscle invasive bladder cancer

B. Ravenscroft, P. Yolmo, S. Chenard, S. Rahimi, K. Pace, K. Sachdeva, T. Jamaspishvilli, H. Ghadei, A. Garven, K. Tyryshkin, D. M. Berman, C. Jackson, D. R. Siemens, M. Koti

This study identifies increased stromal densities of B cells, CD103+ cells, and CD163+ M2-like macrophages as predictors of poor clinical outcomes in BCG-treated NMIBC patients.

bioRxiv · Oct 19, 2023 · PreprintCancer Biology

Sexual dimorphism in outcomes of non-muscle invasive bladder cancer: a role of CD163+ M2 macrophages, B cells and PD-L1 immune checkpoint.

S. Chenard, C. Jackson, T. Vidotto, L. Chen, C. Hardy, T. Jamaspishvilli, D. M. Berman, D. R. Siemens, M. Koti

This study identifies sexual dimorphism in NMIBC immune microenvironment, showing higher CD163+ macrophages and PD-L1 in female tumors, linked to worse recurrence-free survival.

bioRxiv · Jan 23, 2021Immunology